• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 514870 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414057982 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414057982 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Shares of United Therapeutics Under Pressure, Down 2.1%

Published on Mon, 06/10/2013 - 10:55
By Robert Cotter

United Therapeutics (NASDAQ:UTHR) is one of today's biggest movers, down 2.1% to $65.57. The Dow is trading fractionally higher to 15,261 and the S&P is currently trading fractionally higher to 1,645.

United Therapeutics (NASDAQ:UTHR) is currently priced 10.4% above its average consensus analyst price target of $58.78. The stock should discover initial support at its 50-day moving average (MA) of $64.26 and subsequent support at its 200-day MA of $57.05.

United Therapeutics share prices have moved between a 52-week high of $70.74 and a 52-week low of $36.55 and are now trading 79% above that low price at $65.57 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has advanced 0.7%.

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Tesoro: 52-Week High Recently Eclipsed (...

Tesoro (NYSE:TSO) traded at a new 52-week high today of $68.26. This new high was reac ...

Travelers Looks to Continue to Trade Abo...

Shares of Travelers (NYSE:TRV) traded at a new 52-week high today of $96.29. This new ...

Shares of TECO Energy Rise Above Previou...

TECO Energy (NYSE:TE) traded at a new 52-week high today of $19.25. Approximately 2.3 ...

Recent 52-Week High Exceeded in Shares o...

STERIS (NYSE:STE) traded at a new 52-week high today of $58.58. So far today approxima ...

Sovran Self Storage: The Winning Streak ...

Sovran Self Storage (NYSE:SSS) traded at a new 52-week high today of $82.00. So far to ...

Sonic: 52-Week High Recently Eclipsed (S...

Sonic (NASDAQ:SONC) traded at a new 52-week high today of $24.89. Approximately 1.2 mi ...

Snap-On Looks to Continue to Trade Above...

Snap-On (NYSE:SNA) traded at a new 52-week high today of $128.65. Approximately 354,00 ...

Super Micro Computer: The Winning Streak...

Shares of Super Micro Computer (NASDAQ:SMCI) traded at a new 52-week high today of $30. ...